Multidrug Resistance Gene-1 Is a Useful Predictor of Paclitaxel-Based Chemotherapy for Patients with Ovarian Cancer

Author： Kamazawa S.   Kigawa J.   Kanamori Y.   Itamochi H.   Sato S.   Iba T.   Terakawa N.  

Publisher： Academic Press

ISSN： 0090-8258

Source： Gynecologic Oncology, Vol.86, Iss.2, 2002-08, pp. : 171-176

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Paclitaxel-based chemotherapy for patients with refractory or relapsed nonseminomatous germ cell tumors

By Amato R.J.   Prow D.M.  

Urologic Oncology: Seminars and Original Investigations, Vol. 5, Iss. 4, 2000-07 ,pp. : 134-138

Elsevier

Access to resources Recommend Favorite

Multidrug Resistance Mediated by MRP1 Gene Overexpression in Breast Cancer Patients

By Abaan Ogan Demir   Mutlu Pelin Kaya   Baran Yusuf   Atalay Can   Gunduz Ufuk  

Cancer Investigation, Vol. 27, Iss. 2, 2009-02 ,pp. : 201-205

Informa Healthcare

Access to resources Recommend Favorite

Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: The prediction value of ERCC1 and Tau expression

By                

International Journal of Oncology, Vol. 44, Iss. 5, 2014-01 ,pp. : 1736-1744

Spandidos Publications

Access to resources Recommend Favorite

Paclitaxel-Based Chemotherapy in Carcinoma of the Fallopian Tube

By Gemignani M.L.   Hensley M.L.   Cohen R.   Venkatraman E.   Saigo P.E.   Barakat R.R.  

Gynecologic Oncology, Vol. 80, Iss. 1, 2001-01 ,pp. : 16-20

Elsevier

Access to resources Recommend Favorite

NRP1 is targeted by miR-130a and miR-130b, and is associated with multidrug resistance in epithelial ovarian cancer based on integrated gene network analysis

By      

Molecular Medicine Reports, Vol. 13, Iss. 1, 2016-01 ,pp. : 188-196

Spandidos Publications

Access to resources Recommend Favorite